The Institute of Cancer Research, London, has rated second in REF 2021 – the Government’s evaluation of university research quality – among all higher education institutions in the UK that submitted at least two units of assessment.

The Institute of Cancer Research, London, strongly welcomes the news that 177Lu-PSMA-617, a potent radioactive medicine that searches for tumour cells to deliver a radioactive payload, has been approved by the US Food and Drug Administration (FDA) for treating some advanced prostate cancers.

​The 'Man Van', an innovative new outreach programme, has been launched today to provide free health checks for men and boost early diagnosis of prostate and other urological cancers.